GB1603340A - Potentiated acellular vaccines - Google Patents
Potentiated acellular vaccines Download PDFInfo
- Publication number
- GB1603340A GB1603340A GB16933/78A GB1693378A GB1603340A GB 1603340 A GB1603340 A GB 1603340A GB 16933/78 A GB16933/78 A GB 16933/78A GB 1693378 A GB1693378 A GB 1693378A GB 1603340 A GB1603340 A GB 1603340A
- Authority
- GB
- United Kingdom
- Prior art keywords
- ribosomes
- rna
- capsular polysaccharides
- pneumoniae
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 25
- 150000004676 glycans Chemical class 0.000 claims abstract description 57
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 57
- 239000005017 polysaccharide Substances 0.000 claims abstract description 57
- 210000003705 ribosome Anatomy 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000002775 capsule Substances 0.000 claims abstract description 10
- 230000001580 bacterial effect Effects 0.000 claims abstract description 7
- 230000003389 potentiating effect Effects 0.000 claims abstract description 4
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 14
- 239000002244 precipitate Substances 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 241000606768 Haemophilus influenzae Species 0.000 claims description 8
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 8
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 6
- 229940030156 cell vaccine Drugs 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 4
- NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical group CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 claims description 2
- 229960004830 cetylpyridinium Drugs 0.000 claims description 2
- 238000000354 decomposition reaction Methods 0.000 claims description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 229920002477 rna polymer Polymers 0.000 description 26
- 239000012071 phase Substances 0.000 description 15
- 102000003886 Glycoproteins Human genes 0.000 description 14
- 108090000288 Glycoproteins Proteins 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108020004418 ribosomal RNA Proteins 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 239000012133 immunoprecipitate Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000000951 immunodiffusion Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003497 anti-pneumococcal effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940124733 pneumococcal vaccine Drugs 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 235000015842 Hesperis Nutrition 0.000 description 1
- 235000012633 Iberis amara Nutrition 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001727 anti-capsular Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- -1 disodium salt Chemical class 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0266—Klebsiella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7713009A FR2388563A1 (fr) | 1977-04-29 | 1977-04-29 | Vaccins acellulaires perfectionnes contenant des polysaccharides capsulaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1603340A true GB1603340A (en) | 1981-11-25 |
Family
ID=9190107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB16933/78A Expired GB1603340A (en) | 1977-04-29 | 1978-04-28 | Potentiated acellular vaccines |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS53136516A (es) |
| BE (1) | BE866464A (es) |
| CA (1) | CA1103155A (es) |
| CH (1) | CH630806A5 (es) |
| DE (1) | DE2818922A1 (es) |
| ES (1) | ES469225A1 (es) |
| FR (1) | FR2388563A1 (es) |
| GB (1) | GB1603340A (es) |
| IT (1) | IT1156717B (es) |
| NL (1) | NL7804660A (es) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU724862B2 (en) * | 1996-02-14 | 2000-10-05 | Merck Sharp & Dohme Corp. | Polysaccharide precipitation process |
| US6410025B1 (en) | 1996-02-14 | 2002-06-25 | Merck & Co., Inc. | Polysaccharide precipitation process |
| US6503512B1 (en) * | 1993-03-31 | 2003-01-07 | Fernand Narbey Torossian | Anti-AIDS immunomodulator complex |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1115210A (en) * | 1977-11-28 | 1981-12-29 | Dennis J. Carlo | Pneumococcal vaccine |
| US4324887A (en) * | 1978-08-16 | 1982-04-13 | President And Fellows Of Harvard College | Type II group B Streptococci polysaccharide |
| FR2444464A1 (fr) * | 1978-12-19 | 1980-07-18 | Fabre Sa Pierre | Proteoglycanes bacteriens purifies, procede pour leur preparation et vaccin les contenant |
| US4242501A (en) * | 1979-08-08 | 1980-12-30 | American Cyanamid Company | Purification of pneumococcal capsular polysaccharides |
| US4287173A (en) * | 1979-09-24 | 1981-09-01 | Merck & Co., Inc. | Vaccine for dental caries |
| FR2471785A1 (fr) | 1979-12-21 | 1981-06-26 | Fabre Sa Pierre | Preparations immunostimulantes a base d'arn ribosomaux et procede de preparation des arn |
| FR2475900A1 (fr) * | 1980-02-20 | 1981-08-21 | Fabre Sa Pierre | Complexe vaccinal contenant un antigene specifique et vaccin le contenant |
| FR2495939B1 (fr) * | 1980-12-11 | 1985-10-11 | Merieux Inst | Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies |
| BE889979A (fr) * | 1981-08-14 | 1982-02-15 | Smith Kline Rit | Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation |
| GB8906795D0 (en) * | 1989-03-23 | 1989-05-10 | Carroll Noel | Method of preparing vaccines |
| DE4141970C2 (de) * | 1991-12-16 | 1998-02-19 | Charite Med Fakultaet | Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung |
| JPH0651347U (ja) * | 1992-12-21 | 1994-07-12 | 有限会社河上建築事務所 | 軒樋の枯葉止め |
| FR2790961B1 (fr) * | 1999-03-17 | 2001-06-22 | Fabre Pierre Sante | Utilisation d'une composition comprenant des proteoglycanes de klebsiella pneumoniae, et des ribosomes ou des arn ribosomaux bacteriens pour le traitement et/ou la prevention des maladies parodontales |
-
1977
- 1977-04-29 FR FR7713009A patent/FR2388563A1/fr active Granted
-
1978
- 1978-04-27 ES ES469225A patent/ES469225A1/es not_active Expired
- 1978-04-27 BE BE187182A patent/BE866464A/xx not_active IP Right Cessation
- 1978-04-28 IT IT49126/78A patent/IT1156717B/it active
- 1978-04-28 NL NL7804660A patent/NL7804660A/xx not_active Application Discontinuation
- 1978-04-28 CA CA302,203A patent/CA1103155A/fr not_active Expired
- 1978-04-28 DE DE19782818922 patent/DE2818922A1/de not_active Withdrawn
- 1978-04-28 GB GB16933/78A patent/GB1603340A/en not_active Expired
- 1978-04-28 CH CH469078A patent/CH630806A5/fr not_active IP Right Cessation
- 1978-05-01 JP JP5262378A patent/JPS53136516A/ja active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6503512B1 (en) * | 1993-03-31 | 2003-01-07 | Fernand Narbey Torossian | Anti-AIDS immunomodulator complex |
| AU724862B2 (en) * | 1996-02-14 | 2000-10-05 | Merck Sharp & Dohme Corp. | Polysaccharide precipitation process |
| US6410025B1 (en) | 1996-02-14 | 2002-06-25 | Merck & Co., Inc. | Polysaccharide precipitation process |
Also Published As
| Publication number | Publication date |
|---|---|
| IT7849126A0 (it) | 1978-04-28 |
| NL7804660A (nl) | 1978-10-31 |
| FR2388563B1 (es) | 1981-01-09 |
| CH630806A5 (en) | 1982-07-15 |
| JPS53136516A (en) | 1978-11-29 |
| CA1103155A (fr) | 1981-06-16 |
| ES469225A1 (es) | 1978-11-16 |
| FR2388563A1 (fr) | 1978-11-24 |
| DE2818922A1 (de) | 1978-11-09 |
| BE866464A (fr) | 1978-10-27 |
| IT1156717B (it) | 1987-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1603340A (en) | Potentiated acellular vaccines | |
| US4460575A (en) | Vaccinal complex containing a specific antigen and vaccine containing it | |
| US4271147A (en) | Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same | |
| Baker et al. | Studies on immunization against plague: I. The isolation and characterization of the soluble antigen of Pasteurella pestis | |
| CN102257155B (zh) | 控制肺炎链球菌血清型19a多糖分子量的方法 | |
| Ribi et al. | Endotoxic and antigenic fractions from the cell wall of Salmonella enteritidis. Methods for separation and some biologic activities | |
| MacLeod et al. | Stepwise intratype transformation of pneumococcus from R to S by way of a variant intermediate in capsular polysaccharide production | |
| IT1172379B (it) | Procedimento per la produzione di acido ialuronico da colture batteriche | |
| CA1139302A (en) | Process for the preparation of purified bacterial membranal proteoglycans | |
| EP0041897B1 (en) | Polysaccharide antigen from streptococcus and vaccines | |
| EP0008969B1 (en) | Vaccine and method of making | |
| US3976544A (en) | Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction | |
| US4210641A (en) | Novel polysaccharide extracts and method of use | |
| US4349540A (en) | Process for preparing vaccines based on antigenic ribosomal fractions | |
| FI59024C (fi) | Foerfarande foer framstaellning och rening av en antigen till c-gruppen hoerande meningokockpolysackarid som har hoeg molekylvikt och aer aktiv mot av c-gruppens meningokocker orsakad meningit | |
| US4220638A (en) | Antigenic complex from N. Gonorrhoeae | |
| EP0080021B1 (en) | Haemophilus influenzae type b and pertussis outer membrane component combined vaccine | |
| US4367222A (en) | Immune globulin specific to Group B streptococci | |
| US4356263A (en) | Method of making a polysaccharide vaccine | |
| Schwab et al. | IMMUNOLOGICAL STUDIES ON AC POLYSACCHARIDE COMPLEX OF GROUP A STREPTOCOCCI HAVING A DIRECT TOXIC EFFECT ON CONNECTIVE TISSUE | |
| US4248862A (en) | Immunogenic cell envelope preparations | |
| EP0015846A2 (en) | Antigenic sub-cellular cell wall fraction of Bordetella Bronchiseptica, method of obtaining it and composition comprising it | |
| US3269913A (en) | Staphylococcal-immunizing products and methods for their production | |
| JPH0742322B2 (ja) | クレブシェラ属細菌のアシルグリカン、その製造方法及びそれからなる薬剤 | |
| Foley et al. | Studies on the Biology of Cryptococcus: IV. Isolation of a Highly Polymerized Polysaccharide from Encapsulated Strains |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| 732 | Registration of transactions, instruments or events in the register (sect. 32/1977) | ||
| PE20 | Patent expired after termination of 20 years |
Effective date: 19980427 |